{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T05:42:10Z","timestamp":1784612530982,"version":"3.55.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1016\/j.bbmt.2015.08.027","type":"journal-article","created":{"date-parts":[[2015,8,30]],"date-time":"2015-08-30T04:47:40Z","timestamp":1440910060000},"page":"268-276","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["Influence of Absorption, Distribution, Metabolism, and Excretion Genomic Variants on Tacrolimus\/Sirolimus Blood Levels and Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation"],"prefix":"10.1016","volume":"22","author":[{"given":"Samer K.","family":"Khaled","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joycelynne M.","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef","family":"Herzog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracey","family":"Stiller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ni-Chun","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Senitzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueli","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra H.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sepideh","family":"Shayani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Weitzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Forman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9082-0680","authenticated-orcid":false,"given":"Ryotaro","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2015.08.027_bib1","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s00281-004-0165-3","article-title":"Allogeneic hematopoietic cell transplantation as treatment for hematological malignancies: a review","volume":"26","author":"Baron","year":"2004","journal-title":"Springer Semin Immunopathol"},{"key":"10.1016\/j.bbmt.2015.08.027_bib2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1053\/j.seminhematol.2005.09.001","article-title":"Pathophysiology of graft-versus-host disease","volume":"43","author":"Ferrara","year":"2006","journal-title":"Semin Hematol"},{"key":"10.1016\/j.bbmt.2015.08.027_bib3","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.bbmt.2003.12.305","article-title":"Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation","volume":"10","author":"Cutler","year":"2004","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.08.027_bib4","doi-asserted-by":"crossref","first-page":"3108","DOI":"10.1182\/blood-2006-09-046219","article-title":"Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation","volume":"109","author":"Cutler","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.08.027_bib5","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1182\/blood-2009-03-207563","article-title":"A\u00a0phase II pilot study of tacrolimus\/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 conditioning regimens","volume":"115","author":"Rodriguez","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.08.027_bib6","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.3324\/haematol.2012.067140","article-title":"A\u00a0randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation","volume":"97","author":"Pidala","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2015.08.027_bib7","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1182\/blood-2014-04-567164","article-title":"Tacrolimus\/sirolimus vs tacrolimus\/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT","volume":"124","author":"Cutler","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.08.027_bib8","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.bbmt.2012.10.006","article-title":"Thrombotic microangiopathy associated with sirolimus level after allogeneic hematopoietic cell transplantation with tacrolimus\/sirolimus-based graft-versus-host disease prophylaxis","volume":"19","author":"Shayani","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.08.027_bib9","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1097\/00007890-200112270-00010","article-title":"Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease","volume":"72","author":"Benito","year":"2001","journal-title":"Transplantation"},{"issue":"Suppl B","key":"10.1016\/j.bbmt.2015.08.027_bib10","doi-asserted-by":"crossref","first-page":"B93","DOI":"10.1016\/S0149-2918(00)89026-8","article-title":"Toxicity and efficacy of sirolimus: relationship to whole-blood concentrations","volume":"22","author":"Meier-Kriesche","year":"2000","journal-title":"Clin Ther"},{"key":"10.1016\/j.bbmt.2015.08.027_bib11","doi-asserted-by":"crossref","first-page":"283","DOI":"10.2165\/00003088-200140040-00004","article-title":"Comparative clinical pharmacokinetics of tacrolimus in paediatric and adult patients","volume":"40","author":"Wallemacq","year":"2001","journal-title":"Clinical Pharmacokinet"},{"key":"10.1016\/j.bbmt.2015.08.027_bib12","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/sj.bmt.1701331","article-title":"Tacrolimus: a new agent for the prevention of graft-versus-host disease in hematopoietic stem cell transplantation","volume":"22","author":"Jacobson","year":"1998","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.08.027_bib13","doi-asserted-by":"crossref","first-page":"328","DOI":"10.2133\/dmpk.22.328","article-title":"Metabolism of tacrolimus (FK506) and recent topics in clinical pharmacokinetics","volume":"22","author":"Iwasaki","year":"2007","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1016\/j.bbmt.2015.08.027_bib14","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.pharmthera.2006.04.006","article-title":"An up-date review on individualized dosage adjustment of calcineurin inhibitors in organ transplant patients","volume":"112","author":"Masuda","year":"2006","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.bbmt.2015.08.027_bib15","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1097\/TP.0b013e31816fc03b","article-title":"Drug-drug interactions with immunosuppressive agents: review of the in\u00a0vitro functional assays and role of cytochrome P450 enzymes","volume":"85","author":"Elbarbry","year":"2008","journal-title":"Transplantation"},{"key":"10.1016\/j.bbmt.2015.08.027_bib16","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1097\/00007890-199810270-00026","article-title":"Serious interaction between mibefradil and tacrolimus","volume":"66","author":"Krahenbuhl","year":"1998","journal-title":"Transplantation"},{"key":"10.1016\/j.bbmt.2015.08.027_bib17","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/S0168-8278(01)00040-X","article-title":"Identification of cyclosporine A and tacrolimus glucuronidation in human liver and the gastrointestinal tract by a differentially expressed UDP-glucuronosyltransferase: UGT2B7","volume":"34","author":"Strassburg","year":"2001","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.bbmt.2015.08.027_bib18","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1097\/FPC.0b013e3282e9a533","article-title":"1199G>A and 2677G>T\/A polymorphisms of ABCB1 independently affect tacrolimus concentration in hepatic tissue after liver transplantation","volume":"17","author":"Elens","year":"2007","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.bbmt.2015.08.027_bib19","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/FTD.0b013e31816babef","article-title":"Role of pharmacogenetics of immunosuppressive drugs in organ transplantation","volume":"30","author":"Thervet","year":"2008","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.bbmt.2015.08.027_bib20","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/clpt.2009.266","article-title":"Pharmacokinetic and pharmacodynamic interactions between the immunosuppressant sirolimus and the lipid-lowering drug ezetimibe in healthy volunteers","volume":"87","author":"Oswald","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.bbmt.2015.08.027_bib21","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/0163-7258(89)90025-9","article-title":"Clinical pharmacokinetics of cyclosporin","volume":"42","author":"McMillan","year":"1989","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.bbmt.2015.08.027_bib22","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/0003-9861(92)90711-5","article-title":"In\u00a0vitro metabolism of FK-506 in rat, rabbit, and human liver microsomes: identification of a major metabolite and of cytochrome P450 3A as the major enzymes responsible for its metabolism","volume":"294","author":"Vincent","year":"1992","journal-title":"Arch Biochem Biophys"},{"key":"10.1016\/j.bbmt.2015.08.027_bib23","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/86882","article-title":"Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression","volume":"27","author":"Kuehl","year":"2001","journal-title":"Nat Genet"},{"key":"10.1016\/j.bbmt.2015.08.027_bib24","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/bmt.2012.175","article-title":"A\u00a0phase II study of sirolimus, tacrolimus and rabbit anti-thymocyte globulin as GVHD prophylaxis after unrelated-donor PBSC transplant","volume":"48","author":"Khaled","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.08.027_bib25","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.leukres.2012.04.022","article-title":"Reduced intensity allogeneic hematopoietic stem cell transplantation for MDS using tacrolimus\/sirolimus-based GVHD prophylaxis","volume":"36","author":"Nakamura","year":"2012","journal-title":"Leuk Res"},{"key":"10.1016\/j.bbmt.2015.08.027_bib26","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.bbmt.2009.09.020","article-title":"Improved outcomes using tacrolimus\/sirolimus for graft-versus-host disease prophylaxis with a reduced-intensity conditioning regimen for allogeneic hematopoietic cell transplant as treatment of myelofibrosis","volume":"16","author":"Snyder","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.08.027_bib27","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1177\/0091270008319329","article-title":"PhRMA white paper on ADME pharmacogenomics","volume":"48","author":"Williams","year":"2008","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.bbmt.2015.08.027_bib28","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/00007890-197410000-00001","article-title":"Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors","volume":"18","author":"Glucksberg","year":"1974","journal-title":"Transplantation"},{"key":"10.1016\/j.bbmt.2015.08.027_bib29","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/biomet\/73.1.13","article-title":"Longitudinal data analysis using generalized linear models","volume":"73","author":"Liang","year":"1986","journal-title":"Biometrika"},{"key":"10.1016\/j.bbmt.2015.08.027_bib30","doi-asserted-by":"crossref","first-page":"825","DOI":"10.2307\/2532642","article-title":"Estimating equations for parameters in means and covariances of multivariate discrete and continuous responses","volume":"47","author":"Prentice","year":"1991","journal-title":"Biometrics"},{"key":"10.1016\/j.bbmt.2015.08.027_bib31","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1214\/aos\/1176350951","article-title":"A\u00a0class of K-sample tests for comparing the cumulative incidence of a competing risk","volume":"16","author":"Gray","year":"1988","journal-title":"Ann Stat"},{"key":"10.1016\/j.bbmt.2015.08.027_bib32","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A\u00a0Proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J\u00a0Am Stat Assoc"},{"key":"10.1016\/j.bbmt.2015.08.027_bib33","article-title":"Moderne problem der humangenetik","volume":"12","author":"Vogel","year":"1959","journal-title":"Ergeb Inn Med U Kinderheilk"},{"key":"10.1016\/j.bbmt.2015.08.027_bib34","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.2217\/pgs.13.149","article-title":"Pharmacogenetics of antiplatelets and anticoagulants: a report on clopidogrel, warfarin and dabigatran","volume":"14","author":"Ross","year":"2013","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.bbmt.2015.08.027_bib35","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/j.1399-0012.2005.00370.x","article-title":"Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation","volume":"19","author":"Zhang","year":"2005","journal-title":"Clin Transplant"},{"key":"10.1016\/j.bbmt.2015.08.027_bib36","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1111\/j.1600-6143.2005.00745.x","article-title":"Consequences of genetic polymorphisms for sirolimus requirements after renal transplant in patients on primary sirolimus therapy","volume":"5","author":"Anglicheau","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1016\/j.bbmt.2015.08.027_bib37","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/j.1399-3046.2006.00662.x","article-title":"Influence of the CYP3A5 genotype on tacrolimus pharmacokinetics and pharmacodynamics in young kidney transplant recipients","volume":"11","author":"Ferraresso","year":"2007","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.bbmt.2015.08.027_bib38","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1111\/j.1600-6143.2004.00435.x","article-title":"The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation","volume":"4","author":"MacPhee","year":"2004","journal-title":"Am J Transplant"},{"key":"10.1016\/j.bbmt.2015.08.027_bib39","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/FPC.0b013e3282f9ac01","article-title":"Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients","volume":"18","author":"Fukudo","year":"2008","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.bbmt.2015.08.027_bib40","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/S0169-409X(02)00066-2","article-title":"Genetic contribution to variable human CYP3A-mediated metabolism","volume":"54","author":"Lamba","year":"2012","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.bbmt.2015.08.027_bib41","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1097\/00007890-200212150-00002","article-title":"Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement","volume":"74","author":"Macphee","year":"2002","journal-title":"Transplantation"},{"key":"10.1016\/j.bbmt.2015.08.027_bib42","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.clpt.2006.03.012","article-title":"CYP3A5*3 influences sirolimus oral clearance in de novo and stable renal transplant recipients","volume":"80","author":"Le Meur","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.bbmt.2015.08.027_bib43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/bdd.577","article-title":"Association study of ABCB1 and CYP3A5 gene polymorphisms with sirolimus trough concentration and dose requirements in Chinese renal transplant recipients","volume":"29","author":"Miao","year":"2008","journal-title":"Biopharm Drug Dispos"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879115005753?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879115005753?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:54:26Z","timestamp":1761058466000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879115005753"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["S1083879115005753"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2015.08.027","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Influence of Absorption, Distribution, Metabolism, and Excretion Genomic Variants on Tacrolimus\/Sirolimus Blood Levels and Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2015.08.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}